Security key
12529R107
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 54,715,914
- Total 13F value
- $78,242,864
- Share change
- -9,583,907
- SEC-reported price per share
- $1.43
- Number of holders
- 102
- Value change
- -$14,672,718
- Number of buys
- 57
- Number of sells
- 70
- Shares outstanding
- 111,288,493
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
102
Top holders
10
CCCC full security history
Ownership snapshot
Full 13F holder table
C4 Therapeutics, Inc. SEC filings
C4 Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CCCC - C4 Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
Lynx1 Capital Management LP
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
Lead comparable stake: 6.4%
Showing 1-6 of 15 holder rows.
Quick read
Lynx1 Capital Management LP leads the comparable SEC ownership view at 6.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership
Top 5
Lynx1 Capital Management LP
6.4%
Soleus Capital Management, L.P.
6.3%
ORBIMED ADVISORS LLC
6.1%
WASATCH ADVISORS LP
6%
BlackRock, Inc.
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
13F
Company
|
6.4%
|
$11,357,013
7,098,133 shares
|
— | 31 Mar 2025 |
| Soleus Capital Management, L.P. |
13F
Company
|
6.3%
|
$11,166,307
6,978,942 shares
|
— | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
6.1%
|
$10,928,480
6,830,300 shares
|
— | 31 Mar 2025 |
| WASATCH ADVISORS LP |
13F
Company
|
6%
|
$10,759,054
6,724,409 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
4.7%
|
$8,455,060
5,284,413 shares
|
— | 31 Mar 2025 |
| MORGAN STANLEY |
13F
Company
|
3.6%
|
$6,472,526
4,045,329 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
102
Shares
54,715,914
Rows available
102
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
113
Q2 2025 holders
102
Holder diff
-11
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|